Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

Research and Reports in Urology

Volumn 6, Issue , 2014, Pages 97-105

  Zobniw, Chrystia M ^a   Causebrook, Alanna ^b   Fong, Mei Ka ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

CYP17; Drug resistance; Enzalutamide; Glucocorticoid receptor; Pipeline; Radium 223 dichloride; Sipuleucel T

Indexed keywords

EID: 84905908276     PISSN: None     EISSN: 22532447     Source Type: Journal    
DOI: 10.2147/RRU.S29003     Document Type: Review

References (32)

1. SEER Cancer Statistics Factsheets: Prostate Cancer [webpage on the Internet]. National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/prost.html. Accessed February 2, 2014.
2. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9(5):445-452.
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85.
4. Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-245.
6. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276-308.
7. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89(3):552-556.
8. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61(7): 2892-2898.
9. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70(20):7992-8002.
10. de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
11. Ryan CJ, Smith MR, de Bono JS, et al; COU-AA-302 Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148.
12. Kolesar JM. Prostate Cancer. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; 2011:943-945.
13. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011;125(1-2):23-31.
14. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. 2008;8(4):449-457.
15. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454.
16. Yang LP. Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs. 2011;71(15):2067-2077.
17. Hoy SM. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs. 2013;73(18):2077-2091.
18. Zytiga (abiraterone acetate) [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2012.
19. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14(12):1193-1199.
20. Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):479-481.
21. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
22. National Comprehensive Cancer Network. Prostate Cancer (2.2014). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 20, 2014.
23. Scher HI, Fizazi K, Saad F, et al; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
24. PREVAIL Trial Demonstrates Dramatic OS and PFS Improvement with Enzalutamide for Metastatic Prostate Cancer. Genitourinary Cancers Symposium Daily News. January 30, 2014. Available from: http://gucasym.org/prevail-trial-demonstrates-dramatic-os-and-pfs-improvements-enzalutamide-metastatic-prostate-cancer. Accessed June 11, 2014.
25. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med. Epub 2014 Jun 1.
26. Beer TM, Armstrong AJ, Sternberg CN, et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. J Clin Oncol. 2014;32 Suppl 4:Abstr LBA1.
27. Xofigo (radium chloride) [package insert]. Wayne, NJ: Bayer HealthCare, Pharmaceuticals; 2013.
28. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223.
29. Beer TM, Schellhammer PF, Corman JM, et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology. 2013;82(2): 410-415.
30. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802-1807.
31. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7):1807-1812.
32. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790.